Eli Lilly (LLY) Debt Ratio (2009 - 2026)
Eli Lilly posted quarterly Debt Ratio of 0.37 for Q1 2026, down 13.66% year-on-year from 0.43 in Q1 2025, and down 1.55% on a QoQ basis from 0.38 in Q4 2025.
Eli Lilly (LLY) has 18 years of Debt Ratio data on file, last reported at 0.37 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio fell 13.66% year-over-year to 0.37; the trailing twelve-month figure through Mar 2026 stood at 0.37 (down 13.66% YoY), and the FY2025 full-year result was 0.38, down 11.59% from the prior year.
- Debt Ratio for Q1 2026 stood at 0.37, down from 0.38 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.43 in Q1 2025 and bottomed at 0.33 in Q4 2022.
- The 5-year median for Debt Ratio is 0.37 (2026), against an average of 0.38.
- The widest annual swing landed in 2023, when Debt Ratio climbed 20.11%; it then fell 13.66% in 2026.
- A 5-year view of Debt Ratio shows it stood at 0.33 in 2022, then gained by 20.11% to 0.39 in 2023, then grew by 8.45% to 0.43 in 2024, then slipped by 11.59% to 0.38 in 2025, then dropped by 1.55% to 0.37 in 2026.
- The last three Debt Ratio figures came in at 0.37 (Q1 2026), 0.38 (Q4 2025), and 0.37 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 0.37 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.27 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.47 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 0.38 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 0.62 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.39 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.31 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 0.51 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.37 |
| Dec 31, 2025 | 0.38 |
| Sep 30, 2025 | 0.37 |
| Jun 30, 2025 | 0.40 |
| Mar 31, 2025 | 0.43 |
| Dec 31, 2024 | 0.43 |
| Sep 30, 2024 | 0.41 |
| Jun 30, 2024 | 0.40 |
| Mar 31, 2024 | 0.41 |
| Dec 31, 2023 | 0.39 |
| Sep 30, 2023 | 0.35 |
| Jun 30, 2023 | 0.34 |
| Mar 31, 2023 | 0.36 |
| Dec 31, 2022 | 0.33 |
| Sep 30, 2022 | 0.33 |
| Jun 30, 2022 | 0.36 |
| Mar 31, 2022 | 0.35 |
| Dec 31, 2021 | 0.35 |
| Sep 30, 2021 | 0.35 |
| Jun 30, 2021 | 0.35 |
| Mar 31, 2021 | 0.35 |
| Dec 31, 2020 | 0.36 |
| Sep 30, 2020 | 0.39 |
| Jun 30, 2020 | 0.39 |
| Mar 31, 2020 | 0.42 |
| Dec 31, 2019 | 0.39 |
| Sep 30, 2019 | 0.40 |
| Jun 30, 2019 | 0.41 |
| Mar 31, 2019 | 0.42 |
| Dec 31, 2018 | 0.23 |
| Sep 30, 2018 | 0.28 |
| Jun 30, 2018 | 0.29 |
| Mar 31, 2018 | 0.26 |
| Dec 31, 2017 | 0.30 |
| Sep 30, 2017 | 0.31 |
| Jun 30, 2017 | 0.30 |
| Mar 31, 2017 | 0.27 |
| Dec 31, 2016 | 0.27 |
| Sep 30, 2016 | 0.25 |
| Jun 30, 2016 | 0.26 |
| Mar 31, 2016 | 0.23 |
| Dec 31, 2015 | 0.22 |
| Sep 30, 2015 | 0.22 |
| Jun 30, 2015 | 0.22 |
| Mar 31, 2015 | 0.23 |
| Dec 31, 2014 | 0.22 |
| Sep 30, 2014 | 0.16 |
| Jun 30, 2014 | 0.15 |
| Mar 31, 2014 | 0.15 |
| Dec 31, 2013 | 0.15 |
| Sep 30, 2013 | 0.16 |
| Jun 30, 2013 | 0.16 |
| Mar 31, 2013 | 0.17 |
| Dec 31, 2012 | 0.16 |
| Sep 30, 2012 | 0.16 |
| Jun 30, 2012 | 0.17 |
| Mar 31, 2012 | 0.17 |
| Dec 31, 2011 | 0.21 |
| Sep 30, 2011 | 0.21 |
| Jun 30, 2011 | 0.21 |
| Mar 31, 2011 | 0.21 |
| Dec 31, 2010 | 0.22 |
| Sep 30, 2010 | 0.24 |
| Jun 30, 2010 | 0.25 |
| Mar 31, 2010 | 0.25 |
| Dec 31, 2009 | 0.24 |
| Jun 30, 2009 | 0.29 |